2548. Tissue Pharmacokinetics and its Relevance to Patient Care
Session: Symposium: When Does PK/PD Matter for Patient Care?
Saturday, October 6, 2018: 2:50 PM
Room: S 305-314
Keith Rodvolid, Pharmacy Practice, University of Illinois - Chicago, Chicago, IL

Dr. Keith A. Rodvold received his Bachelor of Science in Pharmacy (1978) and Doctor of Pharmacy (1980) degrees from the University of Minnesota. He completed his research fellowship in clinical pharmacokinetics and pharmacology at St. Paul-Ramsey Medical Center and the University of Minnesota (1980-1981). Dr. Rodvold is a Professor of Pharmacy Practice and Professor of Pharmacy in Medicine in the Colleges of Pharmacy and Medicine at the University of Illinois at Chicago. Dr. Rodvold conducts research in the area of clinical pharmacokinetics and pharmacodynamics of anti-infective agents, with a focus on drug penetration and disposition in special populations. Dr. Rodvold has authored more than 175 original research and review publications, 50 book chapters, and co-editor of the textbooks, Drug Interactions in Infectious Diseases (currently in its fourth edition) and Antibiotic Pharmacodynamics. The American College of Clinical Pharmacy presented Dr. Rodvold with the 2003 Russell R. Miller Award in recognition of his sustained and outstanding contributions to the literature of clinical pharmacy. Dr. Rodvold is a former member of the Anti-Infective Drug Advisory Committee and Pediatric Drug Advisory Subcommittee for the Food and Drug Administration. He is an active member of numerous professional societies and has been elected Fellow of the Infectious Diseases Society of America, American College of Clinical Pharmacology, and American College of Clinical Pharmacy.


K. Rodvolid, Entasis; Merck; Medicine Company/Rempex; Paratek; Wockhardt: Consultant , Consulting fee and Speaker honorarium .

<< Previous Presentation | Next Presentation

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.